Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: A follow-up on a Cochrane review

British Journal of Dermatology

Volumn 169, Issue 2, 2013, Pages 250-259

  Gupta, A K ^a,b   Paquet, M ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; DICLOFENAC; FLUOROURACIL; HYALURONIC ACID; IMIQUIMOD; INGENOL MEBUTATE; PLACEBO;

ACTINIC KERATOSIS; ARTICLE; CRYOTHERAPY; DRUG EFFICACY; FOLLOW UP; HUMAN; META ANALYSIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TREATMENT DURATION;

ADJUVANTS, IMMUNOLOGIC; AGED; AMINOLEVULINIC ACID; AMINOQUINOLINES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CRYOTHERAPY; DICLOFENAC; DITERPENES; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; HYALURONIC ACID; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE AGENTS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84881601345     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12343     Document Type: Article

References (52)

1. Callen JP, Bickers DR, Moy RL,. Actinic keratoses. J Am Acad Dermatol 1997; 36: 650-3.
2. Feldman SR, Fleischer AB Jr,. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis 2011; 87: 201-7.
3. Vatve M, Ortonne J-P, Birch-Machin MA, Gupta G,. Management of field change in actinic keratosis. Br J Dermatol 2007; 157: 21-4.
4. Zhao J, van Valkenhoef G, de Brock B, Hillege H,. ADDIS: an automated way to do network meta-analysis. Available at: http://drugis.org/files/addis-mtc- tutorial.pdf (last accessed 6 May 2013).
5. van Valkenhoef G, Tervonen T, Zwinkels T, et al,. ADDIS: a decision support system for evidence-based medicine. Available at: http://drugis.org/ files/addis-dss.pdf (last accessed 6 May 2013).
6. Gupta AK, Paquet M, Villanueva E, Brintnell W,. Interventions for actinic keratoses. Cochrane Database Syst Rev 2012; 12: CD004415.
7. McEwan LE, Smith JG,. Topical diclofenac/hyaluronic acid gel in the treatment of solar keratoses. Australas J Dermatol 1997; 38: 187-9.
8. Wolf JE Jr, Taylor JR, Tschen E, Kang S,. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709-13.
9. Rivers JK, Arlette J, Shear N, et al,. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146: 94-100.
10. PharmaDerm. Solaraze gel: diclofenac sodium 3%-package insert. Available at: https://www.solaraze.com/solaraze/pdf/solaraze-pi.pdf (last accessed 6 May 2013).
11. Jorizzo J, Stewart D, Bucko A, et al,. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis 2002; 70: 335-9.
12. Stockfleth E, Meyer T, Benninghoff B, et al,. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002; 138: 1498-502.
13. Weiss J, Menter A, Hevia O, et al,. Effective treatment of actinic keratosis with 0·5% fluorouracil cream for 1, 2, or 4 weeks. Cutis 2002; 70: 22-9.
14. Chen K, Yap LM, Marks R, Shumack S,. Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial. Australas J Dermatol 2003; 44: 250-5.
15. Gebauer K, Brown P, Varigos G,. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol 2003; 44: 40-3.
16. Pariser DM, Lowe NJ, Stewart DM, et al,. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003; 48: 227-32.
17. Smith S, Piacquadio D, Morhenn V, et al,. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol 2003; 2: 629-35.
18. Jorizzo J, Weiss J, Furst K, et al,. Effect of a 1-week treatment with 0·5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol 2004; 140: 813-16.
19. Lebwohl M, Dinehart S, Whiting D, et al,. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50: 714-21.
20. Photocure. Metvixia cream 16·8%, product insert. 2004 (on file).
21. Piacquadio DJ, Chen DM, Farber HF, et al,. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol 2004; 140: 41-6.
22. Szeimies R-M, Gerritsen M-JP, Gupta G, et al,. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004; 51: 547-55.
23. Korman N, Moy R, Ling M, et al,. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005; 141: 467-73.
24. Ooi T, Barnetson RS, Zhuang L, et al,. Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. Br J Dermatol 2006; 154: 72-8.
25. Alomar A, Bichel J, McRae S,. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007; 157: 133-41.
26. Jorizzo J, Dinehart S, Matheson R, et al,. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007; 57: 265-8.
27. Krawtchenko N, Roewert-Huber J, Ulrich M, et al,. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157 (Suppl. 2): 34-40.
28. Tanghetti E, Werschler P,. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol 2007; 6: 144-7.
29. Pariser D, Loss R, Jarratt M, et al,. Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2008; 59: 569-76.
30. Anderson L, Schmieder GJ, Werschler WP, et al,. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0·025% and 0·05% for actinic keratosis. J Am Acad Dermatol 2009; 60: 934-43.
31. Gebauer K, Shumack S, Cowen PSJ,. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. Br J Dermatol 2009; 161: 897-903.
32. Hauschild A, Stockfleth E, Popp G, et al,. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol 2009; 160: 1066-74.
33. Szeimies R-M, Matheson RT, Davis SA, et al,. Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study. Dermatol Surg 2009; 35: 586-92.
34. Szeimies R-M, Radny P, Sebastian M, et al,. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Br J Dermatol 2010; 163: 386-94.
35. Dirschka T, Radny P, Dominicus R, et al,. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol 2012; 166: 137-46.
36. Lebwohl M, Swanson N, Anderson LL, et al,. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012; 366: 1010-19.
37. Serra-Guillén C, Nagore E, Hueso L, et al,. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes. J Am Acad Dermatol 2012; 66: e131-7.
38. ClinicalTrials.gov. NCT00828568. A therapeutic equivalence study of two imiquimod cream 5% treatments for patients with actinic keratosis. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00828568 (last accessed 6 May 2013).
39. Foley P, Merlin K, Cumming S, et al,. A comparison of cryotherapy and imiquimod for treatment of actinic keratoses: lesion clearance, safety, and skin quality outcomes. J Drugs Dermatol 2011; 10: 1432-8.
40. Fayter D, Corbett M, Heirs M, et al,. A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin. Health Technol Assess 2010; 14: 1-288.
41. Smith SR, Morhenn VB, Piacquadio DJ,. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol 2006; 5: 156-9.
42. Gholam P, Weberschock T, Denk K, Enk A,. Treatment with 5-aminolaevulinic acid methylester is less painful than treatment with 5-aminolaevulinic acid nanoemulsion in topical photodynamic therapy for actinic keratosis. Dermatology 2011; 222: 358-62.
43. Steinbauer JM, Schreml S, Babilas P, et al,. Topical photodynamic therapy with porphyrin precursors-assessment of treatment-associated pain in a retrospective study. Photochem Photobiol Sci 2009; 8: 1111-16.
44. Gaál M, Otrosinka S, Baltás E, et al,. Photodynamic therapy of non-melanoma skin cancer with methyl aminolaevulinate is associated with less pain than with aminolaevulinic acid. Acta Derm Venereol 2012; 92: 173-5.
45. Berman B, Cohen DE, Amini S,. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: overview and investigational topical agents. Cutis 2012; 89: 241-50.
46. Gold MH,. Pharmacoeconomic analysis of the treatment of multiple actinic keratoses. J Drugs Dermatol 2008; 7: 23-5.
47. Gupta AK,. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis 2002; 70: 30-6.
48. Muston D, Downs A, Rives V,. An economic evaluation of topical treatments for actinic keratosis. J Dermatolog Treat 2009; 20: 266-75.
49. Colombo GL, Chimenti S, Di Matteo S, et al,. Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system. G Ital Dermatol Venereol 2010; 145: 573-81.
50. Caekelbergh K, Annemans L, Lambert J, Roelandts R,. Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma. Br J Dermatol 2006; 155: 784-90.
51. Wilson ECF,. Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses. Pharmacoeconomics 2010; 28: 1055-64.
52. Szeimies RM, Karrer S, Radakovic-Fijan S, et al,. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002; 47: 258-62.